Aging and mental health Eating disorders Pharmaceuticals 
Psychiatric Times
JULY 7, 2025
The top 4 disease states this quarter were schizophrenia (41.7%), major depressive disorder (25%), and treatment-resistant depression (16.7%), and suicidal depression (16.7%). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD).
Psychiatric Times
JULY 31, 2025
Igalmi is the first and only FDA-approved orally dissolving sublingual film for mild, moderate, or severe agitation in patients with schizophrenia or bipolar I or II disorder, administered under the supervision of a health care provider. Cingulate Receives $4.3 million as it prepares to submit its NDA at the end of this month.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JULY 2, 2025
FDA Indications, Potential Future Indications, and Areas of Investigation for GLP-1 RAs Soon after their introduction, GLP-1 RAs’ significant weight-lowering effects and health benefits in other medical disorders became apparent, with relatively greater metabolic and weight loss benefits reported with newer GLP-1 RAs and dual agonists.
Mad in America
OCTOBER 18, 2023
R ay Moynihan is an accomplished health journalist and author who has won several awards for his work. He is known for his use of sharp humor, which can be seen in his mock documentary about a fictional illness called ‘Motivational Deficiency Disorder.’ This applies in the mental illness world and everywhere in medicine.
Mad in America
FEBRUARY 12, 2025
His work spans everything from the cultural history of mental illness to mindfulness, death anxiety, and resiliencenot the hollow kind that comes from pretending everythings fine, but the kind that comes from staring into the void and refusing to flinch. On a personal note, Brent has played a foundational role in my own journey.
Expert insights. Personalized for you.
Let's personalize your content